Fcr blocker of autoantibodies

PreclinicalBiologic

Fcr blocker of autoantibodies is one of 39 biologic programs targeting Systemic Sclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic SclerosisActive, not recruiting

Systemic SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Systemic Sclerosis

#DrugCompanyPhaseTrials

Tracleer

Johnson & Johnson

Approved

4 2

Olumiant

Eli Lilly

Approved

1 3

Flagyl

DDePuy Orthopaedics

Approved

1 4

IC-Green

PProvepharm SAS

Approved

1 5

Rituxan

Roche

Phase 3

7 6

Fludara

Sanofi

Phase 3

4 7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

10 8

Mesnex

BBaxter Healthcare Corporation

Phase 3

4 9

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 10

Cellcept

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Systemic Sclerosis1 trial

AUTOANTIBODIES AND SYSTEMIC SCLEROSIS

Not yet recruiting·IIRCCS Ospedale San Raffaele··NCT06502678·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fcr blocker of autoantibodies. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fcr blocker of autoantibodies compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fcr blocker of autoantibodies. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IRCCS Ospedale San Raffaele company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IIRCCS Ospedale San Raffaele

Fcr blocker of autoantibodies

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Systemic Sclerosis1 trial

References

Drug Info

Quick Facts

Related News